老年慢性心力衰竭患者肌少症风险预测列线图的开发与验证
Development and validation of a clinical nomogram for predicting sarcopenia risk in elderly patients with chronic heart failure
该研究基于山西某三甲医院317例≥65岁慢性心力衰竭患者的横断面数据,采用LASSO回归筛选出疲劳、体力活动、小腿围度、BMI和握力五项独立风险因素,构建动态列线图。
研究在317例老年心衰患者中构建并内部验证了含五项指标的列线图,训练与验证组AUC均达0.95以上,可为肌少症筛查提供参考工具。
Introduction
Chronic heart failure (CHF) symbolizes the advanced stage of various cardiovascular diseases. Associated with a higher prevalence, frequent hospital readmissions, and elevated mortality rates, it imposes a significant financial burden on patients, their families, and society. It is now a prominent global public health issue1. The incidence of CHF is on the rise due to the aging population, the coexistence of multiple chronic diseases, and unhealthy lifestyles2. According to the updated 2023 National Heart Failure Guidelines, 20173, there were approximately 64.34 million heart failure patients worldwide. Based on the results of the China Hypertension Survey (CHS 2012–2015), there are an estimated 8.9 million heart failure patients in China, with a weighted prevalence of 1.3% among residents aged ≥ 35 years.
An age-related syndrome, sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass and/or strength, as well as diminished muscular physiological function4. Being an independent risk factor for heart failure-related events, it significantly impacts the quality of life and life expectancy of such patients5. The prevalence of sarcopenia in elderly CHF patients is as high as 20%6. Since sarcopenia may be reversible and preventative, early identification and timely intervention are crucial, even though there are no medications for sarcopenia yet.
Presently, diagnosing sarcopenia is a complex procedure that requires expensive equipment and specialized personnel. Therefore, this study aimed to identify the risk factors for sarcopenia in elderly CHF patients and to develop a simple, efficient as well as personalized nomogram for assessment. This nomogram might provide a valid reference for the early screening and timely interventions regarding sarcopenia in elderly CHF patients.
Methods
Participants
The minimum sample size was determined as 246 using the sample size calculation formula7 and literature data indicating a 20% incidence of sarcopenia among CHF patients (p = 0.2), with a significance level (α) and Z-value of 0.05 and 1.96, respectively. During the study period, consecutive elderly CHF patients who had undergone BIA-based body composition assessment (including ASMI measurement) in the Department of Cardiovascular Medicine at a tertiary hospital in Shanxi Province were screened. Patients without this examination were not eligible for inclusion. Among those with complete clinical data, a total of 317 patients met al.l inclusion criteria and were included in the final analysis. Because the inclusion criteria required complete data for the key variables (including ASMI, grip strength, and anthropometric measurements), the final analytic dataset contained no missing values, and no imputation methods were applied.
The inclusion criteria were: (1) Patient’s age ≥ 65 years, (2) According to the 2018 Chinese CHF guidelines8, those with a diagnosis of CHF, including typical heart failure symptoms, left ventricular ejection fraction (LVEF) < 40%, or LVEF ≥ 40% with elevated brain natriuretic peptide (BNP) levels, must meet at least one of the following criteria: (a) Left ventricular hypertrophy and/or left atrial enlargement as well as (b) Diastolic dysfunction, and (3) Compliance of the patient and their families for participation and cooperation in completing body measurements like grip strength.
The exclusion criteria were: (1) Acute heart failure patients (2) Those with cognitive or consciousness disorders, (3) Patients in critical condition who might experience sudden health changes, (4) Patients contraindicated for body composition analysis, like those with pacemakers, and (5) Patients with missing clinical data.
This study was approved by the Ethics Committee of Traditional Chinese Medicine, Shanxi University.
Survey tools
A risk factor questionnaire was created using the literature reviews, expert opinions, and the study’s practical requirements. This questionnaire included seven aspects and 52 variables: general patient characteristics, disease-related data, activities of daily living, nutritional status, physical activity level, fatigue status, and relevant laboratory indicators.
General characteristics
This section included variables like age, gender, BMI, blood pressure, heart rate, upper arm and calf circumference, grip strength, marital status, living conditions, occupation, smoking and alcohol consumption history, regular sun exposure, and exposure duration, respectively.
Calf circumference was measured at the level of the maximum circumference of the calf (the widest part, corresponding to the bulk of the gastrocnemius muscle) using a non-elastic flexible tape measure. Measurements were taken with the patient in a seated position, knee flexed at approximately 90°, foot flat on the floor, and the right leg was preferred.
Disease-related data
This section comprised heart failure duration, cardiac function (NYHA classification), the presence of other chronic diseases, medication regime, and the number of hospitalizations due to heart failure exacerbations in the previous year.
Relevant laboratory indicators
This section includes test variables like albumin, hemoglobin, BNP, high-sensitivity cardiac troponin-I, and LVEF. Upon admission, all patients fasted for at least eight hours before the collection of these laboratory indicators.
Activities of daily living (ADL)
A modified version of the Barthel Index9 was used to assess ADL. This index included ten items: feeding, bathing, grooming, dressing, toilet usage, managing bowels and bladder, moving from bed to chair, walking 45 m on flat ground, and climbing stairs. With a total score of 100 points, lower scores indicated diminished self-care ability. The scale is categorized as follows: Scores ranged from 0 to 20 points for complete dependence and requiring full care; 25–45 for severe dependence and requiring substantial help; 50–70 for moderate dependence and requiring some help; 75–95 for mild dependence and self-sufficiency, and 100 for complete independence. Cronbach’s alpha coefficient was 0.920.
Nutritional status
The Mini Nutritional Assessment (MNA) helped to evaluate the nutritional status of elderly CHF patients with sarcopenia. Developed by Guigoz et al. in the early 1990s10, it is a comprehensive tool to assess the nutritional status of the elderly. It comprises 18 items across four domains: anthropometric measurements (4 items), general assessment (6 items), dietary assessment (6 items), and self-assessment (2 items), with a maximum total score of 30 points. A score of > 24 indicates good nutritional status, while scores of 17-23.5 and < 17 indicate the risk of malnutrition and malnutrition, respectively. This tool is commonly employed, easy to use, non-invasive, and has high sensitivity as well as specificity of 98% and 96%, respectively. Cronbach’s alpha coefficient was 0.711.
Physical activity level
The Chinese version of the International Physical Activity Questionnaire (IPAQ) was used to assess physical activity. Developed by the International Physical Activity Measurement Working Group in 2001, it includes six parameters: daily work, daily transportation, daily household chores, exercise and sports activities, leisure and recreation, sitting time as well as sleep duration, respectively. Another Chinese study11 has validated the reliability of the IPAQ among elderly populations aged ≥ 60 years. The physical activity intensity was calculated by: MET value × duration of physical activity (min) × frequency per week = physical activity intensity (MET-min/week). The physical activity intensity was classified into three categories: Low, < 600 MET-min/week; Moderate, 600–1500 MET-min/week, and High, > 3000 MET-min/week. Cronbach’s alpha coefficient was 0.810.
Fatigue status
The Chalder Fatigue Scale (CFS) was utilized to assess the fatigue status of elderly CHF patients with sarcopenia over the past month. Developed by Chalder in 199212, this comprised 14 items (CFS-14). Items 1–8 and 9–14 assess physical fatigue (PF) and mental fatigue (MF), respectively. The total score range was 0–14. Responses were scored based on the participant’s subjective feelings with binary choices of “yes” or “no.” The “yes” and “no” responses were scored as 1 and 0 points, respectively. Items 10, 13, and 14 were reverse-scored. Additionally, an 11-item fatigue scale (CFS-11), which is more frequently used in research due to good reliability and validity, has been created by removing three items from the original scale (“Do you feel tired when you start something but find that you cannot continue?”, “Do you find it difficult to concentrate?”, and “Do you still enjoy doing the things you did previously?”)13,14,15. We used CFS-11 to evaluate the fatigue status of elderly CHF patients with sarcopenia. The scoring method was the same as described above; the first 7 and last 4 items represented PF and MF, respectively. While the total score range was 0–11, a total fatigue score of ≥ 4 indicated fatigue16,17.
Sarcopenia screening questionnaire
The sarcopenia screening was conducted using the SARC-F combined with age and BMI (SARC-F + EBM) scale and developed by Kurita et al. in 2019 18. SARC-F + EBM displays higher sensitivity and specificity, compared to the SARC-F alone18,19. According to a study by Wang Yue20, the SARC-F + EBM has the highest sensitivity and specificity of 73.2% and 92.6%, compared to SARC-F and SARC-Calf. This makes it a recommended tool for screening sarcopenia in hospitalized elderly CHF patients. Thus, we used the Chinese version of the SARC-F + EBM scale, translated and adapted by Huang L et al.21. The first five items matched the standard SARC-F scoring criteria. In item 6, corresponding to age, scores of 10 and 0 points were given to patients aged ≥ 75 years and < 75 years, respectively. Similarly, for item 7, corresponding to BMI, scores of 10 and 0 points were given to patients with BMI ≤ 21 kg/m²and > 21 kg/m², respectively. The total score ranged from 0 to 30 points; a score ≥ 11 indicated a positive screening result for sarcopenia.
Of note, this scale was used solely for descriptive characterization of the study population and was not employed for the definitive diagnosis of sarcopenia. The final outcome classification was based exclusively on the AWGS 2019 criteria as described below.
Diagnosis of Sarcopenia
Sarcopenia was diagnosed, based on the Asian Working Group for Sarcopenia (AWGS2019) consensus, 201922. Subsequently, sarcopenia was verified whether either criteria ① + ③ or ① + ② were met.
① Reduced muscle mass: This was measured using bioelectrical impedance analysis (BIA); the appendicular skeletal muscle index (ASMI) should be < 7.0 kg/m²and < 5.7 kg/m² for men and women, respectively.
② Decreased muscle strength: A handgrip dynamometer was used, with the cutoff values being less than < 28 kg and < 18 kg for men and women, respectively.
③ Reduced physical performance: Assessed by either a 6-meter walking speed of < 1.0 m/s or a time of > 12 s to complete five chair stands.
In this study, an EH101 electronic handgrip dynamometer (Guangdong Xiangshan Weighing Apparatus Group Ltd, China) helped to measure handgrip strength. Patients were instructed to use their dominant hand to grip the device handle as strongly as possible while they were seated. The highest value was recorded, accurate to within 0.1 kg, after the test was performed twice.
The limbs’ muscle mass was measured using a body composition analyzer (BCA-2 A; Tsinghua Tongfang Technology Co., Ltd, Beijing, China). Patients had to fast and avoid drinking water for two hours as well as empty their bladder before measurement. The measurement area and electrodes were kept clean, and patients were instructed to wear minimal clothing as well as remove shoes, socks, and any metal accessories, respectively. Throughout the test, the patients remained still and gripped the handle electrodes with their arms extended straight as well as held approximately 30 away from their trunk.
Survey methods
The questionnaires were distributed and collected on-site to perform the survey. The survey’s purpose and significance were explained to the patients and their families when the patients’ conditions were stable and had no impact on their treatment or rest. After obtaining informed consent and completing the questionnaires, measurements like handgrip strength and calf circumference were obtained.
During the survey, the investigators ensured that no suggestions or biases were communicated to the patients or their families. Subsequently, all responses were recorded objectively, accurately, and comprehensively. The questionnaires were immediately reviewed, and any missing or incomplete information was promptly addressed to ensure the completeness and validity of the data collected.
Statistical analysis
To ensure consistency with the original data, data entry was performed by two individuals using SPSS 18.0 software. R Studio 4.4.1 software was used for model construction, validation, and nomogram plotting. Normally and non-normally distributed continuous data were expressed as mean ± standard deviation or median and interquartile range M [Q1, Q3], respectively. Additionally, categorical data were expressed as frequencies (percentages).
Using t-tests or chi-square tests, univariate analysis helped to identify statistically significant variables (p < 0.05). Subsequently, the least absolute shrinkage and selection operator (LASSO) regression was used to determine the optimal independent factors. Furthermore, a multivariate logistic regression analysis was performed with these parameters to identify predictive variables for sarcopenia in elderly CHF patients (p < 0.05).
Because the final analytic dataset contained no missing values for any of the included variables, no missing data imputation methods were applied.
To address potential data separation, we performed a sensitivity analysis using Firth’s penalized maximum likelihood estimation (logistf package in R) to verify the stability of the regression coefficients (Supplementary Table S2).
The “rms,” “ggplot,” and “DynNom” packages in R were used to plot several nomograms. Additionally, the model’s predictive and clinical utilities were evaluated using the area under the ROC curve (AUC), calibration curves, and decision curve analysis (DCA). The ROC curves, calibration curves, and DCA were plotted using the “pROC,” “survival,” and “rmda” packages, respectively. A strong predictive model was indicated by an AUC value of 1. While an AUC value between 0.5 and 0.75 was considered acceptable, an AUC value > 0.75 indicated a good discriminative ability. Statistical significance was denoted if p < 0.05.
Results
General patient characteristics
We included 317 elderly CHF patients, comprising 164 males and 153 females, respectively. Among them, 219 patients did not have sarcopenia, while 98 patients had sarcopenia, resulting in an incidence rate of 30.91%. Table 1 compares the incidence of sarcopenia in elderly CHF patients with different characteristics.
Analysis of risk factors for sarcopenia in elderly CHF patients
A univariate analysis using binary logistic regression was performed. The results indicated that the following factors were significantly associated with sarcopenia occurrence in elderly CHF patients: lipid-lowering drug usage, fatigue, living conditions, nutritional status, heart function classification, self-care ability, marital status, upper arm and calf circumferences, age, BMI, sunlight exposure duration, grip strength, albumin, triglycerides, BNP, and LVEF (p < 0.05).
For variable selection, we performed least absolute shrinkage and selection operator (LASSO) regression using the `glmnet` package in R with 10-fold cross-validation. For this binomial logistic model, we used binomial deviance as the loss function for cross-validation (`type.measure = “deviance"`). The optimal penalty parameter λ was selected as the value that minimized the cross-validated deviance (`lambda.min`). The left and right dashed vertical lines in Fig. 1B represent `lambda.min` and `lambda.1se`, respectively.This λ value was used to select five predictive variables with non-zero coefficients: fatigue, physical activity, calf circumference, BMI, and grip strength (Fig. 1B).
LASSO regression analysis. A. Coefficient pathway diagram B. Cross-validation curve for LASSO regression using binomial deviance as the loss function. The left and right vertical dashed lines represent lambda.min and lambda.1se, respectively.
These five variables were subsequently included in a multivariate logistic regression analysis. Thus, the selected variables—fatigue, physical activity, calf circumference, BMI, and grip strength—were all identified as independent risk factors for sarcopenia occurrence in elderly CHF patients (p < 0.05, Table 2).
Development of a nomogram for predicting the risk of sarcopenia in elderly CHF patients
The multivariate logistic regression analysis results were used to construct a nomogram using the `rms` package, R version 4.4.1. The five independent risk factors predicting sarcopenia in elderly CHF patients (fatigue, physical activity, calf circumference, BMI, and grip strength) were incorporated into it. Each predictive factor was assigned a corresponding value (Point) on the nomogram. Thus, by calculating and summing the scores according to each patient’s specific characteristics, a total score (Total Points) was obtained, corresponding to the sarcopenia rate in the last column (Figs. 2A and B).
(A) The nomogram model (B) Calculation of the nomogram’s total scores according to patients’ specific characteristics.
Validation and clinical application of the risk prediction model
After evaluation, the model showed a C-index of 0.951. Internal validation was performed using 10-fold cross-validation resampling and yielded an AUC of 0.941, a Kappa of 0.705, as well as sensitivity and specificity of 90.71% and 80.25%, respectively. The nomogram prediction model’s ROC curves were plotted for both the training and validation groups. Our results indicated the nomogram’s good predictive ability (training group AUC: 0.955 [95% CI: 0.929–0.980]; validation group AUC: 0.951 [95% CI: 0.907–0.995], Fig. 3). Furthermore, the Hosmer-Lemeshow test helped to assess the model’s goodness of fit. The calibration curve in the training cohort showed close agreement with the ideal line. In the validation cohort, the calibration curve showed overall acceptable agreement (MAE = 0.044), although a modest deviation was observed in the middle probability range (approximately 0.4–0.7), which is likely attributable to the limited sample size of the validation group (n = 96) (Fig. 4).Finally, DCA was performed for the nomogram in both the training and validation groups, respectively. The results demonstrated that the nomogram performed well and could be effectively applied in clinical settings (Fig. 5).
ROC curves of the sarcopenia risk prediction model for elderly CHF patients in the training and validation groups. A. Training Group. B. Validation Group.
The sarcopenia risk prediction model’s calibration curves for elderly CHF patients in the training and validation groups. A. Training Group. B. Validation Group.
DCA of the sarcopenia risk prediction model for elderly CHF patients in both study groups. A. Training Group. B. Validation Group.
Sensitivity analyses
To address the potential incorporation bias arising from grip strength as both a predictor and a diagnostic component of sarcopenia (AWGS 2019), we performed a sensitivity analysis excluding grip strength from the model. The reduced model, comprising fatigue, physical activity, calf circumference, and BMI, yielded an AUC of 0.949 (95% CI: 0.925–0.973), indicating that the nomogram retains excellent discriminative performance even without grip strength (Supplementary Table S1).
Additionally, given the recent release of the AWGS 2025 consensus, we conducted a post-hoc sensitivity analysis reclassifying sarcopenia according to the updated criteria (low muscle mass + low grip strength, with physical performance as outcome indicators). Under this alternative definition, the prevalence of sarcopenia was 29.0%, and the model demonstrated an AUC of 0.964 (95% CI: 0.946–0.982), confirming the robustness of our findings across different diagnostic frameworks (Supplementary Table S3).
Development of a dynamic nomogram for predicting the risk of sarcopenia in elderly CHF patients
Based on the risk prediction nomogram in elderly CHF patients, a dynamic nomogram was constructed using the `DynNom` package, R version 4.4.1.The probability of sarcopenia occurrence and the corresponding 95% CI were directly obtained from the dynamic nomogram summary by using the patient’s fatigue status, physical activity level, calf circumference, BMI, and grip strength in the interface. For example, an elderly CHF patient with fatigue, low physical activity, a calf circumference of 28 cm, a BMI of 18 kg/m², and a 7 kg grip strength had a predicted sarcopenia probability of 92.9%, with a 95% CI of 0.832–0.972 (Fig. 6).
Dynamic nomogram’s user interface for predicting sarcopenia risk in elderly CHF patients. The dynamic nomogram can be launched locally using the DynNom package in R (R Core Team, Vienna, Austria) or is available upon request from the corresponding author.
Discussion
Current status of sarcopenia in elderly CHF patients
Sarcopenia is a common complication in elderly CHF patients and can independently affect a patient’s prognosis. Numerous pathophysiological processes, like reduced cardiac output, systemic congestion, inadequate food intake, decreased exercise capacity, secretion of significant amounts of pro-inflammatory cytokines, increased sympathetic nervous system activity, and immune system activation, can lead to skeletal muscle loss23. Susann et al. in 20136 reported that the sarcopenia prevalence in elderly CHF patients was 20%. The prevalence of sarcopenia among elderly CHF patients in our study was 30.91%, slightly higher than the findings of Susann et al.6. This discrepancy might result from differences in sarcopenia screening tools, sample sizes, racial characteristics, or an increasing global aging population. Additionally, more clinicians are identifying and screening for sarcopenia as research on sarcopenia is deepening. This study’s findings are in line with a 2023 meta-analysis24 that reported a prevalence of 31% for sarcopenia in elderly CHF patients.
The interaction of sarcopenia and CHF creates a vicious cycle that leads to decreased functional capacity, enhanced disability, and higher mortality rates in elderly patients. Early signs of sarcopenia include slower walking, frequent fatigue, and increased risk of falls. These subtle symptoms are usually not detected until there is a significant decline in physical function. Therefore, awareness and screening efforts should be increased for detecting sarcopenia in daily life and clinical practice. Using scientifically validated, simple, and effective tools to screen high-risk populations can help in the early implementation of preventive and intervention measures. Moreover, these measures can slow the progression of sarcopenia, improve quality of life, and reduce the burden of care on patients, families, and society.Given the high prevalence of sarcopenia among elderly CHF patients, it is crucial to further understand its impact on clinical outcomes.
Numerous studies have demonstrated that sarcopenia significantly worsens the prognosis of elderly patients with chronic heart failure (CHF). For instance, a prospective multicenter cohort study conducted in Europe by Fülster et al. reported that sarcopenia was present in 19.5% of CHF patients and was independently associated with increased mortality and hospitalization rates (hazard ratio [HR] for all-cause mortality: 2.12; 95% confidence interval [CI]: 1.30–3.45)6. More recently, a systematic review and meta-analysis involving 14 cohort studies by Yang et al. confirmed that sarcopenia increases the risk of mortality in CHF patients by approximately 68% (relative risk [RR]: 1.68; 95% CI: 1.42–2.00). Furthermore, sarcopenia has been officially recognized as a distinct clinical disease entity in the 11th revision of the International Classification of Diseases (ICD-11), highlighting its critical role in the clinical management of chronic diseases such as heart failure. Together, these findings underscore the substantial impact of sarcopenia on the clinical trajectory of CHF. Early identification and intervention for sarcopenia may therefore play a crucial role in improving survival rates, reducing hospitalizations, and enhancing quality of life among elderly CHF patients.
Risk factors for sarcopenia
Fatigue
Our study indicated that fatigue (OR = 2.916) significantly affected the occurrence of sarcopenia in elderly CHF patients, which was consistent with the findings of Suzan et al.25 which showed that fatigue (OR = 1.161) increases the risk of sarcopenia. Suzan et al. used three different fatigue scales to reveal that sarcopenia patients experience PF, MF, and social fatigue. Fatigue-induced prolonged exhaustion, weakness, and tiredness can decrease daily activities and social interactions, thereby accelerating muscle loss and enhancing the risk of sarcopenia. Another study26 has suggested that inflammatory immune responses and pro-inflammatory cytokine levels can induce fatigue in various diseases. Since sarcopenia is an inflammatory condition, the cytokines involved in its pathogenesis may contribute to fatigue. However, no significant correlation has been observed between fatigue and sarcopenia, but fatigue is significantly associated with slow walking speed and reduced grip strength.26. Therefore, further investigation is needed to explore the relationship between fatigue and sarcopenia. Hence, healthcare providers should advise patients to adopt healthier lifestyles, like avoiding late nights, ensuring adequate rest, and doing moderate exercise. If fatigue is related to underlying diseases, timely medical intervention and personalized treatment should be duly implemented.
Physical activity
Our study found that physical activity level (OR = 0.091) could predict sarcopenia in elderly CHF patients and was consistent with the study by Zhang Hao et al.27 which indicated that diminished physical activity (OR = 1.650) significantly increases the risk of sarcopenia. The reason could be that while reduced physical activity impairs muscle cell metabolism and decreases muscle mass as well as strength, enhanced physical activity improves muscle strength by promoting protein synthesis, reducing low-grade chronic inflammation, and boosting antioxidant effects.28 Low physical activity was also identified as a key risk factor for sarcopenia, with a prevalence 1.44 times higher than that of frequent exercisers29. Additionally, aerobic exercise, when combined with resistance training significantly improves muscle mass and function in elderly sarcopenia patients30. In order to improve patient compliance and optimize benefits, healthcare providers should encourage elderly CHF patients to exercise accordingly, provide personalized exercise prescriptions, and dynamically adjust exercise duration, frequency, intensity, as well as type.
Calf circumference and grip strength
This study showed that calf circumference (OR = 0.808) was associated with sarcopenia in elderly CHF patients. Calf muscles maintain body stability and support motor functions; an enhanced calf circumference also indicates higher muscle mass31. Moreover, calf circumference is highly correlated with muscle mass (r = 0.84 for men and r = 0.86 for women, p < 0.001)32. Another study investigating the relationship between calf circumference and muscle mass in individuals > 40 years old found a significant positive correlation between calf circumference and skeletal muscle mass; however, shorter calf circumferences were associated with a higher risk of sarcopenia in the elderly33. The Chinese Expert Consensus on the Diagnosis and Treatment of Sarcopenia in the Elderly recommends self-screening for sarcopenia by measuring calf circumference34. However, the ideal cutoff values vary throughout the studies because of factors influencing calf circumference, like gender, race, age, and edema35. Therefore, healthcare providers should consider the screened population’s characteristics when using calf circumference for sarcopenia screening. However, CHF patients with edema should undergo multiple dynamic assessments and be evaluated along with other indicators.
Our results also showed that grip strength (OR = 0.919) could significantly predict sarcopenia in elderly CHF patients. Significantly associated with muscle strength, it is a key indicator for assessing physical strength and overall health status in the elderly36,37. During the heart failure progression, reduced cardiac output and systemic congestion lead to diminished food intake and exercise capacity, promote inflammatory responses, increase sympathetic nervous system activity, and alter muscle-related hormone secretions, thereby causing muscle weakness and reduced grip strength38. Therefore, lower grip strength in elderly CHF patients should raise questions regarding sarcopenia occurrence.
BMI
This study found that BMI (OR = 0.790) was a risk factor for sarcopenia occurrence in elderly CHF patients. Being overweight or obese can affect muscle metabolism and release inflammatory mediators. However, excessive fat accumulation inhibits hypothalamic feedback to leptin signals and increases intramuscular lipid content and skeletal muscle fat deposition, leading to lipotoxicity, muscle function disruption, and sarcopenia39,40. Additionally, Fukuoka et al.41 indicated that low BMI and higher body fat percentage increase the risk of sarcopenia. Moreover, low BMI individuals are lean and have poor nutritional status, which significantly increases the risk of sarcopenia42. Yang Le et al.43 found that when BMI was < 18 kg/m², the incidence of sarcopenia was the highest, suggesting that BMI might be a protective factor against sarcopenia. Additionally, the study by Li Xue44 indicated that a BMI cutoff value of 22.45 kg/m²can optimally predicts sarcopenia in elderly CHF patients, with a sensitivity and specificity of 60% and 78.5%, respectively. Thus, these studies suggest that both high and low BMI might cause sarcopenia. Therefore, healthcare providers should precisely assess abnormal BMI patients, prioritize weight management in elderly CHF patients, and develop effective nutrition as well as exercise prescriptions. Nonetheless, maintaining BMI > 22.45 kg/m² might help reduce the risk of sarcopenia.
The sarcopenia risk prediction model for elderly CHF patients is scientifically sound, highly operable, and clinically practical
Accurately predicting the risk of sarcopenia in elderly CHF patients and promptly detecting high-risk individuals is crucial for implementing effective preventive measures and personalized interventions. Consequently, this can significantly minimize adverse clinical events, improve patients’ quality of life, and reduce healthcare burden. Our dynamic nomogram demonstrated good predictive capability through internal validation, with high discriminative power and calibration (training group AUC: 0.955 [95% CI: 0.929–0.980] and validation group AUC: 0.951 [95% CI: 0.907–0.995]). Moreover, it is simple and easy to use. Healthcare professionals can access the nomogram webpage on their mobile devices or computers at any time, enter the relevant values, and obtain the probability of sarcopenia occurrence along with the 95% CI. This can greatly enable them to implement personalized preventive interventions based on the nomogram’s predictive results, making this tool scientifically efficient, highly operable, and clinically practical.
Conclusions
Based on fatigue, physical activity, calf circumference, BMI, and grip strength, our dynamic nomogram demonstrated excellent predictive performance and clinical practicality for assessing sarcopenia occurrence in elderly CHF patients. Furthermore, this tool provides healthcare professionals with an efficient, convenient, practical, and non-invasive method for dynamically evaluating the risk of sarcopenia in such patients. It can also serve as a valid reference for carrying out dynamic assessment and personalized interventions in high-risk populations for sarcopenia.
However, our study had certain limitations. We acknowledge several limitations. First, the AWGS 2025 consensus was published after the completion of our data collection (July 2023 – June 2024). Although our sensitivity analysis using the AWGS 2025 framework confirmed the robustness of our findings (AUC = 0.964), future prospective studies should validate our nomogram using the updated criteria. Second, the inclusion of grip strength as a predictor may introduce incorporation bias, as it is also a diagnostic component of sarcopenia. Nevertheless, our sensitivity analysis excluding grip strength demonstrated that the model maintained good predictive performance (AUC = 0.949), suggesting that the model’s discriminative ability is not solely dependent on this variable. Third, we did not apply correction factors for edema in calf circumference measurements, although univariate analysis showed no significant association between edema and sarcopenia in our cohort. Fourth, the calibration curve in the validation cohort showed some deviation in the intermediate-risk range, likely due to the limited validation sample size (n = 96). Finally, this was a single-center study with a relatively small sample size, and external validation in larger, multi-center cohorts is warranted to further generalize our findings.
References
Benjamin, E. J. et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 137 (12), 67–492. https://doi.org/10.1161/cir.0000000000000558 (2018). [published Online First: 2018/02/02].
Wang, Z. et al. Summary of the 2022 Report on Cardiovascular Health and Diseases in China. Chin. Med. J. (Engl). 136 (24), 2899–2908. https://doi.org/10.1097/cm9.0000000000002927 (2023). [published Online First: 2023/11/29].
National Center for Cardiovascular Diseases, Heart Failure Professional Committee of the National Cardiovascular Disease Expert Committee, Heart Failure Professional Committee of the Chinese Medical Doctor Association. National heart failure guidelines 2023. Chin. J. Heart Fail. Cardiomyopathy. 7 (4), 215–311 (2023).
Mayhew, A. J. et al. Do Different Ascertainment Techniques Identify the Same Individuals as Sarcopenic in the Canadian Longitudinal Study on Aging? J. Am. Geriatr. Soc. 69 (1), 164–172. https://doi.org/10.1111/jgs.16823 (2021). [published Online First: 2020/09/17].
Liu, J. Research progress on the impact of sarcopenia in patients with chronic heart failure. Mod. Diagn. Treat. 34 (6), 839–842 (2023).
Fülster, S. et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur. Heart J. 34 (7), 512–519. https://doi.org/10.1093/eurheartj/ehs381 (2013). [published Online First: 2012/11/28].
Wan, X. & Liu, J. P. Sample size estimation in clinical research:(2) observational study. J. Tradit Chin. Med. 48, 599–601 (2007).
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association; Chinese Heart Failure Association of Chinese Medical Doctor Association. Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2018]. Zhonghua Xin Xue Guan Bing Za Zhi. 46 (10), 760–789. https://doi.org/10.3760/cma.j.issn.0253-3758.2018.10.004 (2018). [published Online First: 2018/10/30].
Wang, Y. L. et al. Rehabilitation functional evaluation (People’s Medical Publishing House, 2008).
Guigoz, Y., Vellas, B. & Garry, P. J. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr. Rev. 54 (1 Pt 2), S59–65. https://doi.org/10.1111/j.1753-4887.1996.tb03793.x (1996). [published Online First: 1996/01/01].
Wang, X. B. Reliability and validity of the long-form International Physical Activity Questionnaire in the Chinese elderly population. Zhongguo Laonianxue Zazhi. 35 (20), 5912–5914. https://doi.org/10.3969/j.issn.1005-9202.2015.20.115 (2015).
Chalder, T. et al. Development of a fatigue scale. J. Psychosom. Res. 37 (2), 147–153. https://doi.org/10.1016/0022-3999(93)90081-p (1993). [published Online First: 1993/01/01].
Morriss, R. K., Wearden, A. J. & Mullis, R. Exploring the validity of the Chalder Fatigue scale in chronic fatigue syndrome. J. Psychosom. Res. 45 (5), 411–417. https://doi.org/10.1016/s0022-3999(98)00022-1 (1998). [published Online First: 1998/12/03].
Wong, W. S. & Fielding, R. Construct validity of the Chinese version of the Chalder Fatigue Scale in a Chinese community sample. J. Psychosom. Res. 68 (1), 89–93. https://doi.org/10.1016/j.jpsychores.2009.05.008 (2010). [published Online First: 2009/12/17].
Cho, H. J. et al. Cross-cultural validation of the Chalder Fatigue Questionnaire in Brazilian primary care. J. Psychosom. Res. 62 (3), 301–304. https://doi.org/10.1016/j.jpsychores.2006.10.018 (2007). [published Online First: 2007/02/28].
Wong, W. S. & Fielding, R. Prevalence of chronic fatigue among Chinese adults in Hong Kong: a population-based study. J. Affect. Disord. 127 (1-3), 248–256. https://doi.org/10.1016/j.jad.2010.04.029 (2010). [published Online First: 2010/06/29].
Mizuno, K. et al. Low visual information-processing speed and attention are predictors of fatigue in elementary and junior high school students. Behav. Brain Funct. 7, 20. https://doi.org/10.1186/1744-9081-7-20 (2011). [published Online First: 2011/06/16].
Kurita, N. et al. SARC-F Validation and SARC-F + EBM Derivation in Musculoskeletal Disease: The SPSS-OK Study. J. Nutr. Health Aging. 23 (8), 732–738. https://doi.org/10.1007/s12603-019-1222-x (2019). [published Online First: 2019/09/29].
Dos Santos, M. R. et al. Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). J. Am. Med. Dir. Assoc. 18 (3), 240–245 (2017). [published Online First: 2016/11/07].
Wang, Y. Screening and correlation study of sarcopenia in elderly patients with chronic heart failure (Shanxi Medical University, 2023).
Huang, L. J. et al. Application study of the Chinese version of the SARC-F scale in the community elderly population. J. Nurs. 35 (19), 85–87 (2022).
Chen, L. K. et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J. Am. Med. Dir. Assoc. 21 (3), 300–307e2. https://doi.org/10.1016/j.jamda.2019.12.012 (2020). [published Online First: 2020/02/09].
Gao, L. & Lu, Y. M. Advances in the diagnosis and treatment of chronic heart failure complicated with sarcopenia and cardiac cachexia. Adv. Cardiovasc. Dis. 44 (7), 598–601 (2023).
Chen, R. et al. Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review. Clin. Cardiol. 46 (3), 260–268. https://doi.org/10.1002/clc.23970 (2023). [published Online First: 2023/01/17].
Suzan, V., Kanat, B. B. & Yavuzer, H. Fatigue and primary sarcopenia in geriatric patients. Rev. Assoc. Med. Bras. 2022;68 (11), 1565–1570. https://doi.org/10.1590/1806-9282.20220662 (1992). [published Online First: 2022/11/17].
Vlietstra, L. et al. Sarcopenia in osteoarthritis and rheumatoid arthritis: The association with self-reported fatigue, physical function and obesity. Plos One. 14 (6), e0217462. https://doi.org/10.1371/journal.pone.0217462 (2019). [published Online First: 2019/06/07].
Zhang, H., Hu, J. W. & Zhao, X. H. Prevalence and influencing factors of possible sarcopenia in middle-aged and elderly people in China. Med. Soc. 36 (8), 44–48 (2023).
Wang, J. et al. Prevalence and associated factors of possible sarcopenia and sarcopenia: findings from a Chinese community-dwelling old adults cross-sectional study. BMC Geriatr. 22 (1), 592. https://doi.org/10.1186/s12877-022-03286-y (2022). [published Online First: 2022/07/20].
He, J. Y. et al. Meta-analysis on the incidence and risk factors of sarcopenia in community-dwelling elderly based on cohort studies. Chin. J. Osteoporos. 28 (3), 426–433 (2022).
Lu, D. L. et al. Exercise intervention for sarcopenia in the elderly. Chin. J. Tissue Eng. Res. 28 (35), 5723–5731 (2024).
Chen, S-T. et al. Analysis of risk factors for sarcopenia in lung cancer patients based on a random forest model. Electron. J. Metab. Nutr. Cancer. 11 (1), 88–95 (2024).
Gonzalez, M. C. et al. Calf circumference: cutoff values from the NHANES 1999–2006. Am. J. Clin. Nutr. 113 (6), 1679–1687. https://doi.org/10.1093/ajcn/nqab029 (2021). [published Online First: 2021/03/21].
Jiang, G. T. et al. Study on the correlation between chronic low back pain, sarcopenia, and vitamin D in elderly people over 60 years old. Chin. J. Osteoporos. 26 (9), 1333–1339 (2020).
Yang, M. et al. Screening Sarcopenia in Community-Dwelling Older Adults: SARC-F vs SARC-F Combined With Calf Circumference (SARC-CalF). J. Am. Med. Dir. Assoc. 19 (3), 277.e1-77.e8. https://doi.org/10.1016/j.jamda.2017.12.016 (2018). [published Online First: 2018/02/27].
Liu, Y. et al. Meta-analysis on the accuracy of sarcopenia screening tools in community-dwelling elderly. Chin. J. Osteoporos. 30 (3), 327–334 (2024).
Ye, C. L. Study on the relationship between grip strength and physical fitness in the elderly and the development of a grip strength device (Shanghai University of Sport, 2014).
Wang, Y. et al. Handgrip strength and the prognosis of patients with heart failure: A meta-analysis. Clin. Cardiol. 46 (10), 1173–1184. https://doi.org/10.1002/clc.24063 (2023). [published Online First: 2023/07/20].
Sato, R. et al. Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature? Curr. Heart Fail. Rep. 19 (6), 400–411. https://doi.org/10.1007/s11897-022-00575-w (2022). [published Online First: 2022/10/20].
Hita-Contreras, F. Traditional body mass index cut-offs in older people: Time for a rethink with altered fat distribution, sarcopenia and shrinking height. Maturitas 113, A1–a2. https://doi.org/10.1016/j.maturitas.2018.03.010 (2018). [published Online First: 2018/03/29].
Marcangeli, V. et al. Impact of high-intensity interval training with or without l-citrulline on physical performance, skeletal muscle, and adipose tissue in obese older adults. J. Cachexia Sarcopenia Muscle. 13 (3), 1526–1540. https://doi.org/10.1002/jcsm.12955 (2022). [published Online First: 2022/03/09].
Fukuoka, Y. et al. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J. Diabetes Investig. 10 (2), 322–330. https://doi.org/10.1111/jdi.12908 (2019). [published Online First: 2018/08/12].
Mei, J. Y., Yu, H. Y. & Xia, X. L. Analysis of factors influencing sarcopenia in the elderly in a certain city. Chin. J. Mod. Med. 27 (10), 85–89 (2017).
Yang, L. et al. The impact of body mass index on the occurrence of sarcopenia in patients with rheumatoid arthritis. J. Anhui Med. Univ. 55 (2), 296–300 (2020).
Li, X. Study on the factors related to sarcopenia in elderly patients with chronic heart failure (Inner Mongolia Medical University, 2023).
来源:Nature 健康护理主题 · nature.com